Section 1 Telehealth for substance use disorder treatment under Medicare
“(I) 1 in-person medical evaluation”
“(II) for purposes of prescribing a controlled substance in schedule III or IV, 1 telehealth evaluation; or”
“(D)
“(i) The term telehealth evaluation means a medical evaluation that is conducted in accordance with applicable Federal and State laws by a practitioner (other than a pharmacist) who is at a location remote from the patient and is communicating with the patient using a telecommunications system referred to in section 1834(m) of the Social Security Act (42 U.S.C. 1395m(m)) that includes, at a minimum—
“(I) audio and video equipment permitting two-way, real-time interactive communication between the patient and distant site practitioner; or
“(II) audio-only for the prescription of a partial opioid agonist for opioid use disorder if video services are unavailable to the patient, due to lack of availability of such technology or lack of adequate broadband access, as determined by the practitioner providing telehealth services and a two-way video telehealth appointment for an in-person medical evaluation or telehealth evaluation that utilizes both audio and visual capabilities is required within 10 days of the audio-only prescription.
“(ii) Nothing in clause (i) shall be construed to imply that 1 telehealth evaluation demonstrates that a prescription has been issued for a legitimate medical purpose within the usual course of professional practice.
“(iii) A practitioner who prescribes the drugs or combination of drugs that are covered under section 303(g)(2)(C) using the authority under subparagraph (A)(i)(II) of this paragraph shall adhere to nationally recognized evidence-based guidelines for the treatment of patients with opioid use disorders and a diversion control plan, as those terms are defined in section 8.2 of title 42, Code of Federal Regulations, as in effect on the date of enactment of this subparagraph.”